NewsNew technology is being introduced by ISA Pharmaceuticals to...

New technology is being introduced by ISA Pharmaceuticals to test cancers


Clinical trials for Amplivant, an adjuvant technology that boosts the immune response to cancer therapy, have begun in the United States. A multicenter clinical trial evaluating the Moditop vaccine, Modi-1, and ISA Pharmaceuticals’ novel technology is currently underway.

Patients with triple-negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer will be given Amplivant adjuvant therapy as part of the first-in-human clinical trial for Modi-1 treatment.

Adjuvants are crucial components of vaccines that increase efficacy, but there is a lack of new, innovative, and effective adjuvants in development to add to a limited arsenal, explained Professor Kees Melief, chief scientific officer, ISA Pharmaceuticals.

As such, this is a significant accomplishment that demonstrates the value of our working relationship with Scancell. The trial provides an additional opportunity to demonstrate the potent adjuvant properties that Amplivant confers on therapeutic vaccines in order to potentially benefit patients with a wide range of solid tumors, “added Melief.

The primary study is an open-label clinical trial designed to evaluate Modi-1’s safety and immunogenicity.

Scancell CEO Lindy Durrant said, “This is the first time we have taken a product from our Moditope platform into cancer patients and it is a major step forward for Scancell and our collaboration with ISA Pharmaceuticals.” “Based on the dramatic regression of large tumors in our preclinical models, we are very excited about the potential of Modi-1.”

Head and neck cancer patients in neoadjuvant treatment will be studied to see if Modi-1 has an effect on enhancing tumor cell infiltration. The term “neoadjuvant” refers to a type of treatment used to help shrink a tumor before a more serious one is administered.

Also read: ClearShark acquisition expands the company’s IT product portfolio

Technology has been James's passion for over a decade. After graduating from the University of Chester with a Bachelor of Arts degree in Journalism in 2006, started writing full-time shortly after. Over the years, he has worked on everything from Windows XP to Red Star OS, but more recently has settled into the Apple ecosystem. A regular contributor at, James writes about iOS, macOS, and Apple hardware.


Please enter your comment!
Please enter your name here

Latest news

Kyle Forgeard’s Net Worth

Most people know Kyle as one of the brains behind the YouTube channel Neck, which he co-founded. Have you...

Billy Evans Net Worth, Biography. Age, Career, and Family

Billy Evans is a prominent American businessman having a net worth of around $10 million. You can find everything...

Patriot One Technologies is selected by Central Bank Center for security technology

The Central Bank Center in Lexington, Kentucky, has chosen Patriot One Technologies' SmartGatewayTM solution to safeguard the entrances to...

Mixed reality headset was reportedly shown off by Apple to the company’s board of directors

According to Bloomberg, Apple's board of directors had a hands-on demo of the company's upcoming mixed-reality headset last week....

5WPR announces creation of a dedicated PR division for travel technology

NEW YORK, May 19th, 2022/PRNewswire/— 5WPR, one of the largest independently-owned PR firms in the United States, has announced...

Thagora Acquires Leading Seating Material Company by LEAR

May 19, 2022/PRNewswire/Southfield, Mich.— As a global leader in automotive seating and electronic systems, Lear Corporation (NYSE: LEA) announced...

Must read

You might also likeRELATED
Recommended to you